|
Mutation Information
|
Mutation Site
|
G130N |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
S |
|
Genotype/Subtype
|
A;D |
|
Viral Reference
|
JN182318.1;
GU456636.1 |
|
Immune Escape
|
Y |
Literature Information
|
PubMed PMID
|
29859062
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2018 |
|
Journal
|
BMC infectious diseases |
|
Title
|
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. |
|
Author
|
Colagrossi L,Hermans LE,Salpini R,Di Carlo D,Pas SD,Alvarez M,Ben-Ari Z,Boland G,Bruzzone B,Coppola N,Seguin-Devaux C,Dyda T,Garcia F,Kaiser R,Köse S,Krarup H,Lazarevic I,Lunar MM,Maylin S,Micheli V,Mor O,Paraschiv S,Paraskevis D,Poljak M,Puchhammer-Stöckl E,Simon F,Stanojevic M,Stene-Johansen K,Tihic N,Trimoulet P,Verheyen J,Vince A,Lepej SZ,Weis N,Yalcinkaya T,Boucher CAB,Wensing AMJ,Perno CF,Svicher V,HEPVIR working group of the European Society for translational antiviral research (ESAR). |
|
Evidence
|
These results were confirmed also when the analysis was focused on LAM-treated patients, thus limiting the impact of anti-HBV drugs on the selection of these mutations (sA128V: 4.4%[16/362] vs 0.5%[2/209], P = 0.008; sP120S: 5.5%[20/362] vs 1%[2/209], P = 0.006; sG130N: 0.3%[1/362] vs 1.9%[4/209], P = 0.063).
|
|
|
HBV Mutation Detail Information